- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02321176
Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood
There is blood-eye barrier in eyes,but some oral medicines can enter in the tissues of eyes.
The primary objective of the study is to study the Pharmacokinetics of Trans-resveratrol and Its three Metabolites in Human Eyes and Blood
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Wang Shuaishuai
- Phone Number: 15623422892
- Email: 949990624@qq.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Medical College of HUST
-
Contact:
- Shuaishuai Wang
- Phone Number: 15623422892
- Email: 949990624@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with rhegmatogenous retinal detachment.
- Male and female patients 18-60 years of age.
- nonsmokers or who smoke<10 cigarettes/day.
- BMI ranging from 19 to 30 kg/m^2 were eligible for the study.
- Patients were considered to be healthy on the basis of electrocardiogram (ECG), and clinical laboratory safety tests (haematology, plasma biochemistry, urinalysis and hepatitis B, hepatitis C and HIV serology) performed at screening.
- Women use measures to avoid conception during the study period (e.g. oral contraceptives, intrauterine devices [IUDs], and condoms).
- Avoid ingesting grapefruit, grapefruit juice or other grapefruit juice containing products, and any herbal-based nutrient supplement or prescribed medications( grapefruit, cranberry, blueberry products, peanuts and peanut butter, grape and grape products, and red wine ) during the same period of time.
- patients should abstain from alcohol-containing beverages at least two days prior to and during the study.
Exclusion Criteria:
- Uncontrolled Blood pressure exceeding diastolic pressure of 100 mm Hg (sitting) during the screening period and uncontrolled diabetes mellitus
- Participation in another simultaneous medical investigation or trial
- Renal failure requiring dialysis or renal transplant or liver dysfunction History of other disease,or other findings giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug, might affect interpretation of the results of the study, or render the subject at high risk from treatment complications.5.IOP over 30 mmHg.
- Any previous retinal laser photocoagulation to the study eye in treatment naive. Any previous intravitreal injection in study eye (triamcinolone or other) in treatment naive.
- Any previous vitrectomy in study eye (posterior or anterior associated with vitreous loss in cataract surgery). Intracapsular cataract extraction (posterior capsule needs to be present).
Aphakia or absence of the posterior capsule in the study eye, Structural damage to the center of the macula in the study eye preexisting to CRVO likely to preclude improvement in visual acuity following the resolution of macular edema, including atrophy of the retinal pigment epithelium, subretinal fibrosis, laser scar(s).
-
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pharmacokinetics,trans-resveratrol
tissues from the eyes of the surgery of patients who received 1 Longevinex containing 100 mg of trans resveratrol active ingredient brand capsule for three days
|
patients received 100mg Longevinex everyday,total of three days 1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: up to three days
|
1 capsule containing 100 mg of trans resveratrol active ingredient daily for three days.Than detect the concentrations of the tissues from the eyes of the surgery.
|
up to three days
|
Collaborators and Investigators
Investigators
- Study Director: Sun Xufang, Department of Ophthalmology,Tongji Hospital, Tongji Medical College, Huazhong University of science and Technology
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Sun2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eye Disease
-
National Eye Institute (NEI)RecruitingInherited Eye DiseaseUnited States, United Kingdom, China, Pakistan, Philippines, Ukraine, India, Italy
-
National Eye Institute (NEI)Recruiting
-
National Eye Institute (NEI)RecruitingGenetic Eye DiseaseUnited States
-
OptovueCompletedNo Eye DiseaseUnited States, United Kingdom
-
Bausch & Lomb IncorporatedCompletedDry Eye Disease (DED)United States
-
Augusta UniversityRecruitingCataract; Eye DiseaseUnited States
-
Laboratorios Sophia S.A de C.V.Not yet recruitingOcular Surface Disease | Dry Eye Disease
-
Kahramanmaras Sutcu Imam UniversityCompletedEye Diseases | Dry Eye | Ocular Surface DiseaseTurkey
-
Beaver-Visitec International, Inc.CompletedAphakia, Postcataract | Cataract; Eye DiseaseGermany, France, Spain
-
Centre hospitalier de l'Université de Montréal...Fonds de recherche en ophtalmologie de l'Université de MontréalRecruitingGlaucoma | Eye Diseases | Cornea DiseaseCanada
Clinical Trials on trans-resveratrol
-
Poznan University of Medical SciencesUniversity of California, DavisUnknownPolycystic Ovary Syndrome (PCOS)Poland
-
MaineHealthAmerican Heart AssociationActive, not recruitingCoronary Artery Disease | Diabetes Mellitus, Type 2United States
-
Bernard FiorettiCompleted
-
Maastricht University Medical CenterDSM Nutritional Products, Inc.; Diabetes FondsCompleted
-
Khoo Teck Puat HospitalNational Medical Research Council (NMRC), SingaporeCompleted
-
Universidade Federal FluminenseCompletedChronic Renal Insufficiency
-
Hospital Universitario Pedro ErnestoCompletedEndothelial Dysfunction
-
Northumbria UniversityCompleted
-
Bial - Portela C S.A.Completed
-
Northumbria UniversityCompleted